Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | antazoline | 2200 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | antazoline | 2200 | drug-path |
| Shigellosis | 0 | map05131 | antazoline | 2200 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | antazoline | 2200 | drug-path |
| Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | antazoline | 2200 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | vinpocetine | 68827 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | vinpocetine | 68827 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | vinpocetine | 68827 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | vinpocetine | 68827 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | vinpocetine | 68827 | drug-path |
| Asthma | R-HSA-444620 | map05310 | vinpocetine | 68827 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | vinpocetine | 68827 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | vinpocetine | 68827 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | vinpocetine | 68827 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | vinpocetine | 68827 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | vinpocetine | 68827 | drug-path |
| Tight junction | R-HSA-2134514 | map04530 | vinpocetine | 68827 | drug-path |
| Calcium signaling pathway | R-HSA-381753 | map04020 | vinpocetine | 68827 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | dimethadione | 3081 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | dimethadione | 3081 | drug-path |